Sepsis and septic shock. Sepsis, unspecified organism
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive midodrine tablet 10 mg three times a day (Takeda Pharmaceutical Company., Austria) concomitant with the standard care of septic
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with age over 18 years old Patients with diagnosis of septic shock (need for intravenous vasopressor to maintain MAP= 65 mmHg Serum lactate level over 18 mg/dL
Exclusion criteria
Exclusion criteria: ?More than 24 hours of septic shock diagnosis Chronic kidney disease (eGFR < 30 ml/min) Urinary disorders and neurogenic bladder Heart failure (Ejection Fraaction < 50%) Moderate to severe valvular diseases Pulmonary hypertension and PAP= 45 mmHg Peripheral arterial disease Scleroderma Heart rate below 60 beats per minute Recent history of midodrine use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum lactate. Timepoint: Two times a day (up to when serum lactate level set to <18 mg/dL). Method of measurement: Colorimetric. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lactate clearance. Timepoint: Daily. Method of measurement: Calculation (Comparing two daily serum lactate levels). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Khalili
Tehran University of Medical Sciences
Outcome results
None listed